Michael F. Brigham
Known title: DirectorCIK: 0001136544
Associated companies
Transaction History
| ICCC | ▲ Buy | Option Exercise | 25,000 | $146K | 3/20/2026 | View on chart |
| ICCC | ▼ Sell | Tax Withholding | 24,052 | $146K | 3/20/2026 | View on chart |
| ICCC | ▲ Buy | Option Exercise | 25,000 | $146K | 3/20/2026 | View on chart |
| ICCC | ▼ Sell | Tax Withholding | 24,052 | $146K | 3/20/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ICCC featured in research roundup alongside major tech and pharma names
ImmuCell Corporation was included in a recent Yahoo Finance article highlighting top research reports for Alphabet, Mastercard, and AbbVie. This mention places ICCC in the same discussion as large-cap companies, though the specific details of the research for ICCC are not provided in the summary. The stock currently trades within its 52-week range, with a trailing P/E of 115.1.
ICCC featured in research roundup alongside major tech and pharma names. ImmuCell Corporation was included in a recent Yahoo Finance article highlighting top research reports for Alphabet, Mastercard, and AbbVie. This mention places ICCC in the same discussion as large-cap companies, though the specific details of the research for ICCC are not provided in the summary. The stock currently trades within its 52-week range, with a trailing P/E of 115.1.